Bristol Myers Squibb reported fourth‐quarter product sales of $12.3 billion, a 7 percent increase year-over-year, driven by double‐digit growth in oncology and immunology franchises. Eliquis sales rose 11 percent to $3.8 billion, while Opdivo revenue increased 15 percent to $2.4 billion. Operating income margin expanded 120 basis points to 32.5 percent, reflecting manufacturing efficiencies and disciplined expense management.

In a pivotal Phase 3 adolescent trial, Camzyos achieved its primary endpoint with a 30 percent reduction in composite cardiovascular events compared to control, while improving peak oxygen uptake by 12 percent. The safety profile remained consistent with adult studies, with no new serious adverse events reported across 150 participants. These results extend Bristol Myers Squibb’s leadership in hypertrophic cardiomyopathy and bolster near-term regulatory filings in both the U.S. and EU.

The board approved a 5 percent increase to the quarterly dividend, raising the payout to $0.60 per share, marking the 12th consecutive year of dividend growth. Concurrently, management authorized a $5 billion share repurchase program, of which $1.8 billion has been executed year-to-date. These actions support a dividend yield of approximately 3.1 percent and reflect confidence in free cash flow generation, projected at $11 billion for the full year.

Among 21 brokerage firms covering the stock, 62 percent carry a buy rating, 33 percent hold and only 5 percent recommend sell. The consensus target price implies mid-single-digit upside. Institutional ownership stands at 76.4 percent, one of the highest in the large-cap pharmaceutical sector, suggesting confidence from pension funds and endowments in the company’s long-term growth trajectory.